A cute ST elevation myocardial infarction (STEMI) is the leading cause of mortality and morbidity in Malaysia and is the most deadly type of acute coronary syndrome.1 Urgent invasive or non-invasive reperfusion therapy followed by evidence-based pharmacotherapy are the mainstay of treatment. However, timely invasive percutaneous coronary intervention (PCI) and the adherence to evidence-based pharmacotherapy are still a huge challenge in developing countries. Our population has a high burden of cardiovascular...
Mortality of STEMI Patients

local risk factors. Local data shows that around 16% of patients undergoing PCI are younger than the age of 45; the elderly tend to be undertreated both pharmacologically and invasively. Improving clinical outcomes is of utmost importance and adherence to guideline-based treatment is crucial in determining the outcome.

The Malaysian National Cardiovascular Disease Acute Coronary Syndrome (NCVD-ACS) Registry is an ongoing prospective registry first established in 2006. It started with 8 hospitals in 2006, but currently involves 18 hospitals across Malaysia. The registry was initiated to collect clinical data including in-hospital management and clinical outcome. The NCVD-ACS Registry is sponsored by the Ministry of Health Malaysia and co-sponsored by National Heart Association of Malaysia. The Clinical Research Centre of Malaysia provides technical support in the form of clinical epidemiology expertise, biostatistics and information and communication technology services. Through this concerted effort, we were able to analyze changes in demographic and clinical characteristics as well as the quality of hospital management and clinical outcomes. We used the NCVD-ACS Registry to analyze adherence to guideline-based STEMI treatment and assess how clinical outcomes have changed over recent years.

PATIENTS AND METHODS

Source of data
Anonymised patient data were obtained from the Malaysian NCVD-ACS registry for years 2006 to 2013. The NCVD-ACS registry is sponsored by the Ministry of Health Malaysia and co-sponsored by the National Heart Association of Malaysia. Selected patients were those diagnosed with ST-elevation MI from 18 participating hospitals across Malaysia. Data was collected upon admission and throughout the patient stay using a standardized case report form. A unique national identification number was given to each patient to avoid duplication. Follow-up was done at 30 days through phone calls or when patients came to the clinic review. A cross check with the national death registry was also done to verify mortality status. Records were taken of patient ethnicity was based on self-reporting and the national identity card. STEMI is defined as a persistent ST-segment elevation of ≥1 mm in two contiguous electrocardiographic leads or the presence of a new left bundle branch block in the setting of positive cardiac markers.

Statistical method and analysis
Continuous variables were expressed as mean and standard deviation and differences between the years were analyzed using the t test. Categorical variables were described as numbers (percentages), and differences were analyzed using the chi-square test or the Fisher exact test. To avert biases in the estimates and loss of power, missing data for explanatory variables were assumed to be missing at random. In the analysis of inhospital and 30-day all-cause mortalities, all significant variables from a univariate analysis were adjusted to produce a final result for in-hospital and 30-day adjusted risk ratios comparing all sub-groups. A generalized linear model with a log link, binomial distribution, and a robust variance estimator was used to estimate the risk ratios. The risk ratios represent the relative risk for mortality of the patients in year 2006 - 2007 compared to the other three groups. Variables that were statistically significantly different (a two-sided P value of less than .05) between the years, that were of clinical importance, and that had sufficient outcomes in the respective sub-categories were adjusted for in the model. All analyses were conducted using SPSS statistical software (version 21, IBM SPSS Statistics, USA).

RESULTS

The patient population was predominantly ethnic Malay (more than 50%) with a strong male dominancy (more than 85%) (Table 1). The majority of patients fell into the 41 to 60 year-old age group. The prevalence of Malay ethnicities and young patients (<40 years old) trended upward over the study period. Smoking was the most prevalent risk factor followed by hypertension and diabetes mellitus. This pattern remained consistent throughout the years with no clear changes. Among the relevant comorbidities, previous myocardial infarction (MI) was most common followed by chronic renal disease and cerebrovascular disease. All conventional cardiovascular risk factors and related comorbidities remained stable with no marked changes over the years. A large majority of STEMI patients were in Killip class 1 or 2 on presentation. However, there was a steady increase in Killip 4 (cardiogenic shock) presentations.

Intravenous thrombolysis was the main mode of reperfusion therapy throughout the study years (Table 1).
### Table 1. Demographics, risk factors and premorbid conditions.

|                | 2006-2007 | 2008-2009 | 2010-2011 | 2012-2013 | P       |
|----------------|-----------|-----------|-----------|-----------|---------|
| **Age**        |           |           |           |           |         |
| <40            | 227 (7.7) | 262 (8.6) | 400 (8.5) | 750 (9.5) | .013    |
| 41-<60         | 1692 (57.1)| 1667 (54.5)| 2653 (56.5)| 4416 (55.9)|         |
| 61-<80         | 978 (33.0)| 1051 (34.3)| 1519 (32.3)| 2569 (32.5)|         |
| >80            | 68 (2.3)  | 81 (2.6)  | 124 (2.6) | 159 (2.0) |         |
| **Gender**     |           |           |           |           |         |
| Male           | 2663 (85.5)| 2731 (85.0)| 4169 (85.3)| 7109 (86.0)| .493    |
| Female         | 451 (14.5)| 482 (15.0)| 720 (14.7)| 1158 (14.0)|         |
| **Ethnicity**  |           |           |           |           | <.001   |
| Malay          | 1661 (53.3)| 1786 (55.6)| 2795 (57.2)| 5034 (60.9)|         |
| Chinese        | 657 (21.1)| 618 (19.2)| 898 (18.4)| 1281 (15.5)|         |
| Indians        | 605 (19.4)| 600 (18.7)| 808 (16.5)| 1257 (15.2)|         |
| Others         | 191 (6.1) | 209 (6.5) | 388 (7.9) | 695 (8.4) |         |
| **Diabetes mellitus** |       |           |           |           | <.001   |
|                | 1133 (36.4)| 1136 (35.4)| 1816 (37.1)| 2980 (36.0)|         |
| **Hypertension** |         |           |           |           | <.001   |
|                | 1517 (48.7)| 1584 (49.3)| 2454 (50.2)| 4151 (50.2)|         |
| **Smoking**    |           |           |           |           | <.142   |
| Active/former  | 2111 (70.3)| 2087 (68.6)| 3234 (68.6)| 5553 (70.2)|         |
| Never          | 892 (29.7)| 955(31.4) | 1478 (31.4)| 2359 (29.8)|         |
| **Dyslipidaema** |       |           |           |           | <.001   |
|                | 656 (21.1)| 851 (26.5)| 1335 (27.3)| 2085 (25.2)|         |
| FHx Premature CAD |       |           |           |           | <.001   |
|                | 372 (11.9)| 345 (10.7)| 598 (12.2)| 880 (10.6)|         |
| Previous MI    | 329 (10.6)| 377 (11.7)| 530 (10.8)| 890 (10.8)| <.001   |
| Chronic Lung Ds| 67 (2.2)  | 78 (2.4)  | 118 (2.4) | 137 (1.7) | <.001   |
| Cerbrovascular Ds | 95 (3.1) | 72 (2.2)  | 120 (2.5) | 227 (2.7) | <.001   |
| Peripheral Vascular Ds | 11 (0.4) | 10 (0.3)  | 22 (0.5)  | 12 (0.1)  | <.001   |
| Chronic Renal Ds | 106 (3.4)| 103 (3.2) | 174 (3.6) | 263 (3.2) | <.001   |
| Killip Class   |           |           |           |           | <.001   |
| Class I        | 1699 (65.9)| 1725 (64.4)| 2643 (64.6)| 4396 (61.3)|         |
| Class II       | 593 (23.0)| 653 (24.4)| 843 (20.6)| 1452 (20.3)| <.001   |
| Class III      | 125 (4.8) | 110 (4.1) | 201 (4.9) | 324 (4.5) |         |
| Class IV       | 161 (6.2) | 189 (7.1) | 406 (9.9) | 997 (13.9) |         |
| Urgent reperfusion therapy |       |           |           |           | <.001   |
| Thrombolysis   | 2235(74.0)| 2400 (77.6)| 3628 (76.5)| 5712 (70.6)|         |
| Primary PCI    | 229 (7.6) | 180 (5.8) | 408 (8.6) | 1099 (13.6)|         |
| Not Given (missed/ contraindicated/others) | 557 (18.) | 514 (16.7) | 731 (14.9) | 1285(15.6) | <.001   |
| Door to needle time (median minutes) | 55 | 48 | 41 | 45 | <.001 |

Data are n (%) unless otherwise noted.
The median door-to-needle time shortened slightly from 55 minutes in 2006/2007 to 45 minutes in 2012/2013. The use of primary PCI also increased but rather slowly from 7.6% in 2006/2007 to 13.6% in 2012/2013.

The overall invasive and pharmacological treatments are presented in Table 2. Even though the rate of primary PCI did not drastically change over the study period, we observed a significant increase in in-hospital cardiac catheterisations and PCI (including primary PCI) over the study period (Table 2). The percentage of cardiac catheterisation/PCI more than doubled from 2006/2007 (catheterisation 20.6%, PCI 19.2%) to 2012/2013 (catheterisation 47.7%, PCI 41.2%).

The use of evidence-based oral therapies steadily increased over the years, achieving rates of more than 85% in aspirin, adenosine diphosphate receptor antagonist and statin use. The use of ADP-antagonist showed the biggest improvement with an increase from 63.8% (2006/2007 group) to 86.1% (2012/2013 group). The use other pharmacotherapies all showed a gradual improvement except for ACE/ARB where the rate was about the same throughout.

Table 2. Evidence-based pharmacotherapy and invasive coronary intervention (coronary catheterisation).

| Variable          | 2006-2007 | 2008-2009 | 2010-2011 | 2012-2013 | P  |
|-------------------|-----------|-----------|-----------|-----------|----|
| Catheterisation   | 642 (20.6%) | 723 (22.5%) | 1172 (25.7%) | 3761 (47.7%) | <.001 |
| PCI               | 599 (19.2%) | 598 (18.6%) | 990 (23.5%) | 3151 (41.2%) | <.001 |
| Caspirin          | 2335 (89.0%) | 2524 (88.9%) | 4013 (92.5%) | 6786 (92.7%) | <.001 |
| ADP antagonist    | 1630 (63.8%) | 1996 (71.7%) | 3574 (84.2%) | 3152 (86.1%) | <.001 |
| Beta blocker      | 1708 (66.4%) | 1750 (64.1%) | 2801 (68.5%) | 5084 (71.9%) | <.001 |
| ACE-I/ARB         | 1595 (52.4%) | 1519 (49.0%) | 2536 (52.4%) | 4334 (52.4%) | <.001 |
| Statin            | 2290 (88.1%) | 2351 (83.7%) | 3835 (89.2%) | 6567 (89.7%) | <.001 |

No significant changes were seen in the in-hospital mortality through the years except for the drop in mortality in 2010-2011 group (Tables 3 and 4). The mortality rate then slightly increased in 2012-2013 although still lower than the 2006/2007 and 2008/2009 groups. When compared to the 30-day mortality rate in 2006/2007, we observed a generalised decrease in mortality and achieved a significant drop in adjusted risk ratios for the 2010/2011 (RR 0.777 95% CI 0.673-0.897, P=.001) and 2012/2013 groups (RR 0.773 95% CI 0.679-0.881, P<.001) (Table 5).

**DISCUSSION**

In developed western countries, the adoption of timely coronary reperfusion as well as guideline-based pharmacotherapy over the last decade has correlated with an up to 25% reduction in both in-hospital and post-discharge ACS-related mortality. Although there is an encouraging increase in the rate of in-hospital catheterization/PCI for STEMI patients, we are still behind in terms of the actual primary PCIs. In-hospital mortality remained constant throughout these years. The

Table 3. Clinical outcomes (unadjusted all-cause mortality).

| Year     | 2006-2007 | 2008-2009 | 2010-2011 | 2012-2013 | P  |
|----------|-----------|-----------|-----------|-----------|----|
| In-hospital | 295 (9.8%) | 272 (8.8%) | 383 (8.0%) | 696 (8.6%) | .052 |
| 30-day   | 378 (12.1%) | 362 (11.3%) | 474 (9.7%) | 798 (9.7%) | <.001 |

Table 4. Adjusted relative mortality risk compared to the 2006/2007 sub-group In Hospital.

| Variables       | No. of patients | No. (%) of deaths | P     | Adjusted risk ratio* (95%CI) |
|-----------------|-----------------|-------------------|-------|----------------------------|
| STEMI (n=19483) |                 |                   |       |                            |
| 2006-2007       | 3114            | 295 (9.5%)        | .182  | 1.00 (0.748-1.057)         |
| 2008-2009       | 3213            | 272 (8.5%)        | .006  | 0.799 (0.682-0.937)        |
| 2010-2011       | 4889            | 383 (7.8%)        | .052  | 0.868 (0.752-1.001)        |
| 2012-2013       | 8267            | 696 (8.4%)        |       |                            |
cumulative mortality at 30 days postdischarge showed a steady decrease but could have been better.

Realising this issue, the Ministry of Health, in conjunction with Ministry of Education and National Heart institute, initiated a greater Kuala Lumpur STEMI network in late 2015. This network between government hospitals, academic university hospitals and the National Heart institute refers acute STEMI patients directly to PCI capable centres for primary PCI. The aim is to provide access to primary PCI for all patients with STEMI. The network is still at an early stage of development, and due to limitations in supporting staff and facilities, is only active during office hours. Nevertheless we hope to develop this network into a 24-hour service within the next few years.

According to the multinational Global Registry of Acute Coronary Events (GRACE), the use of optimal revascularization and statin use could prevent up to 32% and 10% of death by 6 months, respectively, which clearly demonstrates the additional mortality benefits of pharmacotherapy. Although our cohort shows that rates of aspirin, ADP-antagonist and statin use are all more than 85%, a poor prescribing rate for ACE-I/ARB and beta-blocker persists. Unfortunately, pharmacotherapy costs to patients remains a significant barrier. Hence there is ongoing nationwide effort to increase the availability of generic formulations to ease the cost strain to patients.

Analysis of several other acute coronary syndrome registries around the Asia Pacific region shows some discrepancies. Even though local guidelines in Australia and New Zealand are generally comparable to those of Western countries there are variabilities in the guidelines in other countries. These registries suggest that there is still much room for improvement. A recent effort was the Asia-Pacific real world evidence on outcome and treatment of ACS (APRICOT) project which assembled leading academic teams from several countries across the Asia Pacific region. The APRICOT working group has recommended a few key strategic steps towards improvement in outcome: longer-term patient surveillance, greater patient education (pain awareness, compliance, primary/secondary prevention), overcoming geographical challenges to pre-hospital and post-discharge care, and adoption of a value-based over cost-based healthcare system. A limitation of the study is that it used retrospective registry data that varies among hospitals.

In conclusion, the standard of in-hospital management of STEMI is still sub-optimal in Malaysia and the mortality rate remains high. The rate of primary PCI as the reperfusion strategy is very low as well. Although IV thrombolysis is still relevant in our clinical setting, it should not continue to be the default reperfusion treatment as it has been shown to be inferior to primary PCI. On-going efforts are now being done to improve STEMI care. The greater KL STEMI network started in late 2015 and we look forward to see how it will improve STEMI care and overall clinical outcomes. Treating physicians need to be more aware of the importance of evidence-based pharmacotherapy and more generic based medications need to be introduced to ease the cost burden to our patients.

Acknowledgments

We would like to thank all medical and non-medical personnel who have participated and contributed to the NCVD-ACS registry.

This NCVD registry study was approved by the Medical Review & Ethics Committee (MREC), Ministry Of Health (MOH) Malaysia in 2007 (Approval Code: NMRR-07-20-250). MREC waived informed consent for NCVD.

Table 5. Adjusted 30-day relative mortality risk compared with 2006/2007 subgroup.

| Variables       | No. of patients | No. (%) of deaths | P     | Adjusted risk ratio* (95%CI) |
|-----------------|-----------------|-------------------|-------|-----------------------------|
| STEMI (n=19483) |                 |                   |       |                             |
| 2006-2007       | 3114            | 378 (12.1%)       | .281  | 1.00                        |
| 2008-2009       | 3213            | 362 (11.3%)       | .001  | 0.919 (0.788-1.071)         |
| 2010-2011       | 4889            | 474 (9.7%)        | <.001 | 0.777 (0.673-0.897)         |
| 2012-2013       | 8267            | 798 (9.7%)        | <.001 | 0.773 (0.679-0.881)         |
REFERENCES

1. Wan Ahmad WA, Sim KH. Annual report of the NCVD-ACS registry, year 2007 & 2008. Kuala Lumpur Malaysia: National Cardiovascular Disease Database 2010.

2. Mustapha S, Omar Z, Mihat O, Md Noh K, Hassan N, Abu Bakar R et al. Addressing non-communicable diseases in Malaysia: an integrative process of systems and community. BMC Public Health 2015; 14 Suppl 2:S4. doi: 10.1186/1471-2458-14-S2-S4.

3. AS Zuhdi, Mariapun J, Mohd Hairi NN, Wan Ahmad WA, Abidin IZ, Undow AW et al. Young coronary artery disease in patients undergoing percutaneous coronary intervention. Ann Saudi Med 2011; 31(6): 572-8.

4. AS Zuhdi, Ahmad WA, Zaki RA, Mariapun J, Ali RM, Sari NM et al. The elderly in acute coronary syndrome: the Malaysian National Cardiovascular Database-Acute Coronary Syndrome (NCVD-ACS) Registry. Singapore Med J 2015; 36(6):1677-84.

5. Jenberg T, Johanson p, Held C, Svennblad B, Lindback J, Wallentin L. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305(16):1677-84.

6. H. Boden, B.L. van der Hoeven, I. Karalis, M.J. Schalij, J.W. Jukema. Management of acute coronary syndrome: achievements and goals still to pursue. Novel developments in diagnosis and treatment. J. Intern. Med. 271 (2012) 521–536.

7. C.B. Granger, P.G. Steg, E. Peterson, et al., Medication performance measures and mortality following acute coronary syndromes, Am. J. Med. 118 (2005) 858-865.

8. KA Fox, OH Daboub, RJ Goldberg et al. Prediction of risk of death and myocardial infarction in the 6 months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006; 333: 1091.

9. C.W. Hamm, J.P. Bassand, S. Agewall, et al., ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), Eur. Heart J. 32 (2011) 2999-3054.

10. PG. Steg, S.K. James, D. Atar, et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation, Eur. Heart J. 33 (2012) 2569–2619.

11. H. Jneid, J.L. Anderson, R.S. Wright, et al., 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association guideline for the management of ST-elevation myocardial infarction: an update of the 2004 guideline for management of patients presenting with ST-elevation myocardial infarction: an update of the 2004 guideline for management of patients presenting with ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation 126 (2012) 875–910.

12. FT. O’Gara, F.G. Kushner, D.D. Ascheim, et al., 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 127 (2013) e362-e425.

13. New Zealand 2012 guidelines for the management of non ST-elevation acute coronary syndromes, N. Z. Med. J. 125 (2012) 122–147.

14. ST-elevation myocardial infarction: New Zealand management guidelines, N. Z. Med. J. 118 (2005) U1679.

15. J.L. Anderson, C.D. Adams, E.M. Antman, et al., 2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, Circulation 127 (2013) e663–e828.

16. China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Guideline of non-ST segment elevation acute coronary syndrome, Zhonghua Xin Xue Guan Bing Za Zhi 40 (2012) 353–367.

17. Chinese expert consensus for antiplatelet therapy in non-revascularization patients with acute coronary syndrome working group. Chinese expert consensus for antiplatelet therapy in non-revascularization patients with acute coronary syndrome (amendment), Zhong Guo Yi Kan 46 (2011) 79–85.

18. China Society of Cardiology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Guideline for diagnosis and treatment of patients with ST-elevation myocardial infarction, Zhonghua Xin Xue Guan Bing Za Zhi 38 (2010) 675–690.

19. MY Chan, X Du, D Eccleston, C Ma,PP Mohanan, M Ogita et al. Acute coronary syndrome in the Asia-Pacific region. International Journal of Cardiology 2016; 202: 861-869.